MX2011008879A - Estrogen receptor ligands and methods of use thereof. - Google Patents
Estrogen receptor ligands and methods of use thereof.Info
- Publication number
- MX2011008879A MX2011008879A MX2011008879A MX2011008879A MX2011008879A MX 2011008879 A MX2011008879 A MX 2011008879A MX 2011008879 A MX2011008879 A MX 2011008879A MX 2011008879 A MX2011008879 A MX 2011008879A MX 2011008879 A MX2011008879 A MX 2011008879A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- estrogen receptor
- receptor ligands
- reducing
- prostate cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pain & Pain Management (AREA)
Abstract
The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting advanced prostate cancer and palliative treatment of advanced prostate cancer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15470709P | 2009-02-23 | 2009-02-23 | |
US16898309P | 2009-04-14 | 2009-04-14 | |
US26166909P | 2009-11-16 | 2009-11-16 | |
PCT/US2010/025032 WO2010096801A1 (en) | 2009-02-23 | 2010-02-23 | Estrogen receptor ligands and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2011008879A true MX2011008879A (en) | 2012-04-30 |
MX340753B MX340753B (en) | 2016-07-25 |
Family
ID=42634248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011008879A MX340753B (en) | 2009-02-23 | 2010-02-23 | Estrogen receptor ligands and methods of use thereof. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2398322A4 (en) |
JP (1) | JP5611991B2 (en) |
KR (3) | KR20150135547A (en) |
CN (1) | CN102413692B (en) |
BR (1) | BR112014004008A2 (en) |
CA (1) | CA2753436C (en) |
IL (1) | IL214805A0 (en) |
MX (1) | MX340753B (en) |
RU (1) | RU2543339C2 (en) |
WO (1) | WO2010096801A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9409856B2 (en) | 2005-11-28 | 2016-08-09 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
US9623021B2 (en) | 2007-01-22 | 2017-04-18 | Gtx, Inc. | Nuclear receptor binding agents |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
US9624161B2 (en) | 2009-02-23 | 2017-04-18 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
WO2010141630A1 (en) * | 2009-06-03 | 2010-12-09 | University Of Southern California | Compositions and methods for treatment of cancer by disrupting the lh/lhr signaling pathway |
IN2014DN01959A (en) * | 2011-08-23 | 2015-05-15 | Gtx Inc | |
WO2013142390A1 (en) * | 2012-03-21 | 2013-09-26 | Gtx, Inc. | Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors |
WO2014039820A1 (en) * | 2012-09-07 | 2014-03-13 | Gtx, Inc. | Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors |
WO2023220117A1 (en) * | 2022-05-10 | 2023-11-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods of treating dilated cardiomyopathy and heart failure |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020192310A1 (en) * | 2001-02-02 | 2002-12-19 | Bland Jeffrey S. | Medical composition for managing hormone balance |
US20060287282A1 (en) * | 2001-06-25 | 2006-12-21 | Steiner Mitchell S | Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof |
US7601739B2 (en) * | 2003-08-08 | 2009-10-13 | Virgina Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases |
US8158828B2 (en) * | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
CN102702013B (en) * | 2005-11-28 | 2016-02-10 | Gtx公司 | Nuclear receptor binding agents |
US8546451B2 (en) * | 2005-11-28 | 2013-10-01 | Gtx, Inc. | Estrogen receptor ligands and methods of use thereof |
-
2010
- 2010-02-23 KR KR1020157033005A patent/KR20150135547A/en not_active Application Discontinuation
- 2010-02-23 CA CA2753436A patent/CA2753436C/en not_active Expired - Fee Related
- 2010-02-23 WO PCT/US2010/025032 patent/WO2010096801A1/en active Application Filing
- 2010-02-23 JP JP2011551292A patent/JP5611991B2/en not_active Expired - Fee Related
- 2010-02-23 RU RU2011137324/15A patent/RU2543339C2/en not_active IP Right Cessation
- 2010-02-23 KR KR1020117022324A patent/KR101458539B1/en not_active IP Right Cessation
- 2010-02-23 EP EP10744458A patent/EP2398322A4/en not_active Withdrawn
- 2010-02-23 MX MX2011008879A patent/MX340753B/en active IP Right Grant
- 2010-02-23 CN CN201080017935.0A patent/CN102413692B/en not_active Expired - Fee Related
- 2010-02-23 KR KR1020137020249A patent/KR20130101146A/en active IP Right Grant
-
2011
- 2011-08-23 IL IL214805A patent/IL214805A0/en unknown
-
2012
- 2012-08-23 BR BR112014004008A patent/BR112014004008A2/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MX340753B (en) | 2016-07-25 |
EP2398322A4 (en) | 2012-12-05 |
CA2753436A1 (en) | 2010-08-26 |
JP5611991B2 (en) | 2014-10-22 |
AU2010215809A1 (en) | 2011-09-22 |
RU2543339C2 (en) | 2015-02-27 |
KR20150135547A (en) | 2015-12-02 |
BR112014004008A2 (en) | 2017-03-28 |
KR101458539B1 (en) | 2014-11-10 |
KR20130101146A (en) | 2013-09-12 |
WO2010096801A1 (en) | 2010-08-26 |
EP2398322A1 (en) | 2011-12-28 |
JP2012518654A (en) | 2012-08-16 |
CA2753436C (en) | 2016-05-24 |
IL214805A0 (en) | 2011-11-30 |
CN102413692A (en) | 2012-04-11 |
KR20110131227A (en) | 2011-12-06 |
RU2011137324A (en) | 2013-03-27 |
CN102413692B (en) | 2015-01-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX340753B (en) | Estrogen receptor ligands and methods of use thereof. | |
PL2434891T3 (en) | Methods for treating cancer and non-neoplastic conditions | |
HRP20150437T1 (en) | Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer | |
AP2012006277A0 (en) | Method for treating androgen receptor positive cancers. | |
IN2012DN02046A (en) | ||
ZA201202256B (en) | Methods and compositions for treating cancer | |
WO2011020119A3 (en) | Methods of treating cancer using glucagon-like hormone retargeted endopeptidases | |
EP2384221A4 (en) | Methods for reducing discomfort during electrostimulation, and compositions and apparatus therefor | |
WO2010003057A3 (en) | Treating cancer | |
HK1198243A1 (en) | METHOD OF TREATING PROSTATE CANCER WITH GNRH ANTAGONIST GnRH | |
ZA200902814B (en) | Compositions and methods for diagnosing, treating, and preventing prostate conditions | |
WO2014011220A3 (en) | A method of treating androgen receptor (ar)-positive breast cancers with selective androgen receptor modulator (sarms) | |
AP2012006253A0 (en) | Use of toll-like receptors and agonist for treating cancer. | |
EP2512240A4 (en) | Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions | |
WO2007127010A3 (en) | Diarylthiohydantoin compounds | |
IL224370B (en) | Combination treatment for prostate carcinoma | |
NZ601588A (en) | Methods for treating breast cancer | |
IL231107A (en) | Aryl-hydrocarbon receptor (ahr) inhibitor for treating and/or preventing kynurenine-dependent cancer | |
EP2419136A4 (en) | Compositions and methods for treating cancer | |
EP2396034A4 (en) | Antibodies and methods for treating estrogen receptor-associated diseases | |
HUP0900639A2 (en) | Procedure to secure and initiate identified bankcard payment transaction, software for the said purpose and communication equipment containing such software | |
RS56809B1 (en) | Vap-1 inhibitors for use in treating fibrotic conditions | |
EP2661175A4 (en) | Combination steroid and glucocorticoid receptor antagonist therapy | |
WO2012170742A3 (en) | Treatment and prevention of cancer with hmgb1 antagonists | |
DK201270089A (en) | Fulvestrant in a dosage of 50mg for the treatment of advanced cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |